After having discussed a possible application with the Expert in Residence, applicants are asked to discuss their potential application with their usual OUI contact. Their OUI contact will be able to help advise them on completing the IP sections of the IP form, and discuss any questions they may have.

LAB282 is managed operationally on behalf of the University and OUI by Dr Richard Reschen, Senior Licensing & Ventures Manager. He is happy to answer any questions relating to the LAB282 scheme from University academics, where they do not have an existing OUI contact.

DR CHRISTINE WHYTE

Senior Licensing & Ventures Manager

Christine has responsibility for managing the LAB282 initiative. 

She obtained a first class honours degree in Microbiology from the University of Bristol then obtained a DPhil at the University of Oxford, studying gene expression in bacteria.

Prior to joining OUI in 2007, Christine held roles in Unilever, the diagnostics company Oxoid (now part of Thermo Fisher Scientific), Cancer Research Technology and Oxxon Therapeutics

DR PAUL ASHLEY

Head of Licensing & Ventures, Life Sciences
Oxford University Innovation Ltd.

Paul has an undergraduate degree in Zoology and research experience in neuro-physiology and behaviour. Paul’s PhD and post-doc roles investigated mood disorders and pain.

Moving away from the bench, Paul became the CEO of a spin-out company, commercialising remote monitoring and biotelemetry technology developed at the Defence Science Technology Laboratory. Following this, Paul took up a role at AstraZeneca as a member of the management team at the company’s environmental risk assessment facility.

Paul joined Oxford University Innovation as a Deputy Head of Technology Transfer in July 2011 and has overseen a team of life science Technology Transfer Managers commercialising large numbers of technologies across the breadth of the life sciences, licensing and creating companies in fields including biotech and drug discovery,  medical devices, diagnostics, genomics and digital health.

Lab282 Partners

Slide LAB282 is a partnership between the University of Oxford, Oxford University Innovation Ltd, Oxford Sciences Innovation plc (OSI) and Evotec AG, created to identify and develop new approaches to treating disease.

Privacy Policy | Cookie Policy

© LAB282 2019. All rights reserved
LAB282 is a partnership between the University of Oxford, Oxford University Innovation Ltd, Oxford Sciences Innovation plc (OSI) and Evotec AG, created to identify and develop new approaches to treating disease.

Privacy Policy | Cookie Policy

© LAB282 2019. All rights reserved